PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.

ABSTRACT:

Background

The treatment for advanced primary hepatocellular carcinoma (HCC) is sorafenib (SORA), while HCC has become increasingly drug resistant with enhanced aerobic glycolysis. The present study aimed to examine the chemotherapeutic effects of a flavonoid proanthocyanidin B2 (PB2) on HCC.

Methods

Five kinds of HCC cell lines and LO2 were used to test the effect of PB2 on aerobic glycolysis. The proliferation, cell cycle, apoptosis and a xenograft mouse model were analyzed. Lentivirus overexpressed pyruvate kinase M2 (PKM2) or sh-PKM2 was used to verify the target of PB2. The detailed mechanism was investigated by immunofluorescence, co-immunoprecipitation, and western blotting.

Results

PB2 inhibited the proliferation, induced cell cycle arrest, and triggered apopt

SUBMITTER: Feng J 

PROVIDER: S-EPMC6525465 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature